Catalyst Wire Dossier Catalyst Wire Dossier

NNC9204-0530

· Novo Nordisk A/S
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NNC9204-0530, covering 2017-07-27 to 2017-07-27. Get the full timeline:

Most recent: Clinical Trial Update: Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects [Phase 1]

See pricing